|
|
Volumn 23, Issue 2, 2005, Pages 155-156
|
|
Antiinfective biotechs face partnering gap
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFECTIVE AGENT;
DALBAVANCIN;
DAPTOMYCIN;
LIPOPEPTIDE;
OXAZOLIDINONE DERIVATIVE;
PEPTIDE DEFORMYLASE INHIBITOR;
RIFAXIMIN;
TELITHROMYCIN;
TELRITHROMYCIN;
UNCLASSIFIED DRUG;
BIOTECHNOLOGICAL PRODUCTION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
HOSPITAL INFECTION;
MULTIDRUG RESISTANCE;
NOTE;
PRIORITY JOURNAL;
STAPHYLOCOCCUS AUREUS;
ANTI-INFECTIVE AGENTS;
BIOTECHNOLOGY;
DRUG INDUSTRY;
INTERINSTITUTIONAL RELATIONS;
INVESTMENTS;
OWNERSHIP;
UNITED STATES;
STAPHYLOCOCCUS AUREUS;
|
|
EID: 13844281080
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0205-155 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|